Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study

Author:

Tarantino Michael D.1ORCID,Hardesty Brandon2ORCID,Metjian Ara3,Ortel Thomas L.4,Chen Jie5,Badejo Kayode5ORCID,Ma Alice6,Cuker Adam7,Rajasekhar Anita8,Friedman Kenneth D.9,Janbain Maissaa10

Affiliation:

1. Bleeding and Clotting Disorders Institute Peoria Illinois USA

2. Indiana Hemophilia and Thrombosis Center Indianapolis Indiana USA

3. University of Colorado Anschutz Medical Campus Aurora Colorado USA

4. Duke University Durham North Carolina USA

5. Takeda Development Center Americas Inc. Cambridge Massachusetts USA

6. University of North Carolina Chapel Hill North Carolina USA

7. Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

8. Department of Hematology/Oncology University of Florida Health Gainesville Florida USA

9. Medical College of Wisconsin and Versiti/Blood Center of Wisconsin Milwaukee Wisconsin USA

10. Tulane School of Medicine New Orleans Louisiana USA

Abstract

AbstractIntroductionRecombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).AimTo provide long‐term real‐world safety and effectiveness data for rpFVIII in the management of AHA bleeding episodes.MethodsUS PASS (NCT02610127) was a multicentre, uncontrolled, open‐label, post‐marketing safety surveillance study conducted in adults with AHA. Data were collected retrospectively or prospectively for 180 days after rpFVIII treatment. The primary outcome was the incidence of treatment‐related serious adverse events (SAEs). Secondary outcomes included haemostatic effectiveness of rpFVIII and rpFVIII utilization.ResultsFifty‐three patients were enrolled from December 2015 to June 2019 (prospective, n = 30; retrospective, n = 23). Six patients experienced seven treatment‐related SAEs (incidence 12.0%). The most common treatment‐related SAE was FVIII inhibition (inhibiting antibodies to rpFVIII; incidence 8.0%, 95% CI: 2.2–19.2). Five patients reported seven thromboembolic events; one was an SAE and possibly related to rpFVIII. Of bleeding events treated with rpFVIII, 80.3% (57/71) of bleeds resolved with rpFVIII. The median (range) dose of rpFVIII per infusion was 50 (10–300) units/kg, with a median (range) of 6.0 (1–140) infusions and a median (range) time from bleed onset to bleed resolution of 14.0 (2.0–132.7) days.ConclusionIn this real‐world study of rpFVIII for AHA, no new safety signals were identified compared with previous clinical trial findings. Eighty percent of bleeds resolved with rpFVIII treatment.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3